David Nikodem, Ph.D.

David Nikodem, Ph.D. has extensive work experience in various leadership and advisory roles in the biotechnology and pharmaceutical industry. David is currently the Chief Executive Officer at Metadeq Diagnostics, Inc. since January 2023. Prior to this, they served as the Consulting VP of US Operations at Inventiva Pharma starting from September 2018. Before that, they founded and managed Sapidus Partners, LLC from January 2014. David has also worked as an Advisor, Special Projects at Castle Biosciences, Inc. from April 2022 to August 2022. David gained significant experience as the Chief Executive Officer at AltheaDx, Inc. from December 2018 to April 2022 after initially serving as a Director since 2016. Additionally, they held leadership positions at Ally Bridge Group as a Partner and Managing Director (Biopharmaceuticals) from March 2014 to July 2019, and at EXANE ASSET MANAGEMENT as a Portfolio Manager from December 2010 to August 2013. David'searly career includes working as a Portfolio Manager at BNP Paribas from August 2005 to January 2009.

David Nikodem, Ph.D. completed their education spanning from 1985 to 1999. David attended Phillips Exeter Academy from 1985 to 1987. Following that, they pursued a double major in English Language and Literature, and Chemistry at the University of Virginia from 1987 to 1991, earning a Bachelor of Arts - BA degree. David furthered their educational journey at Georgetown University from 1994 to 1999, obtaining a Ph.D. in Biochemistry and Molecular Biology.